43rd CIOSP discusses the future of cannabinoid therapies in Dentistry

Lecture led by specialist will address scientific updates, clinical use, and regulation of cannabinoid therapies in Dentistry during the event in São Paulo

Published on 01/22/2026

43º CIOSP debate o futuro das terapias canabinoides na Odontologia

The perspectives of cannabinoid therapies in Dentistry will be the subject of discussion at the CFO Arena, an exclusive space of the Federal Council of Dentistry (CFO), next Thursday (29).

The 43rd edition of the International Congress of Dentistry of São Paulo (CIOSP) highlights in its program the advances and perspectives of cannabinoid therapies in Dentistry. The topic will be discussed at the CFO Arena, an exclusive space of the Federal Council of Dentistry (CFO), next Thursday (29).

The lecture will be conducted by João Paulo Tanganeli, a specialist and president of the Working Group on Cannabinoids of the Regional Council of Dentistry of São Paulo (CROSP). The meeting promises to bring crucial updates for clinical practice.

Scientific evidence of cannabinoid therapies in Dentistry

João Paulo Tanganeli, president of CROSP. Image: Disclosure

The specialist will provide a historical overview of the topic, presenting updated recommendations and scientific evidence. Tanganeli will also address the positive impacts of the recent standardization of Teleodontologia and future prospects for treatments.

The use of herbal medicines based on Cannabis sativa has grown considerably in recent years. The dental class follows this evolution, incorporating therapy especially in cases of orofacial, neuropathic, and nociplastic pain.

"In recent years, cannabinoid therapy has shown to be a very promising resource and, in some areas, already presents robust evidence for its use," says Tanganeli. He emphasizes that the lecture will detail the legal and regulatory progress and the products available on the market.

Mechanism of action and clinical indications

The mechanism of action of cannabinoid medications occurs through the Endocannabinoid System (ECS), which helps regulate various physiological processes. Compounds such as tetrahydrocannabinol (THC) and cannabidiol (CBD) interact with the body's natural receptors, helping to regulate sleep, mood, appetite, and pain response.

"We have observed very positive results in patients with chronic pain, especially those with pain refractory to other treatments," highlights the specialist about the application of cannabinoid therapies in Dentistry.

These medications are often indicated for bruxism, Temporomandibular Joint Disorders (TMJ), and orofacial pain. However, cannabis use is not the first therapeutic option; Anvisa recommends its prescription after the use of established therapies that did not achieve the expected result.

Teleodontologia and new regulations

CFO booth at the 42nd CIOSP. Image: Disclosure

A central point of the discussion will be the relationship between cannabinoid therapies in Dentistry and Teleodontologia. With Resolution CFO No. 278/2025, the possibility of distance prescription via teleconsultation is opened, expanding access and safety in patient care.

The lecture is part of the CFO Arena program, located at the Autarquia booth at the 43rd CIOSP. The initiative aims to promote technical-scientific and educational debates, bringing together topics of high relevance to the dental class.